» Articles » PMID: 16785989

Cooperation of Oncogenic K-ras and P53 Deficiency in Pleomorphic Rhabdomyosarcoma Development in Adult Mice

Overview
Journal Oncogene
Date 2006 Jun 21
PMID 16785989
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Human rhabdomyosarcomas (RMSs) frequently demonstrate genetic alterations in ras and p53. To investigate their possible involvement in the tumorigenesis, we generated a knock-in mouse line with oncogenic K-ras, conditionally expressed by Cre/LoxP system on a background of p53 alteration. Electroporation of Cre expression vector in skeletal muscle tissues resulted in the generation of tumor in adults with tumor incidences of 100% at 10 weeks and 40% at 15 weeks, in p53(-/-) and p53(-/+) backgrounds, respectively. The tumor histology was pleomorphic RMS with characteristic bizarre giant cells, positive for desmin and alpha-sarcomeric actin and exhibiting remarkable increase in total and phosphorylated extracellular signal-regulated protein kinase (ERK)1 and ERK2. Loss of the wild-type p53 was detected in K-rasG12V-expressed tumors of p53(-/+) mice. Early lesions 3 weeks after electroporation consisted of proliferating populations of myogenic progenitors, including stem cells positive for ScaI antigen, immature cells positive for desmin and neural cell adhesion molecule-positive myotubes. Thus, cooperation of oncogenic K-ras and p53 deficiency resulted in the development of pleomorphic RMS in adult mice, providing a useful mouse model for further detailed studies.

Citing Articles

The Rat Sarcoma Virus (RAS) Family of Proteins in Sarcomas.

Unat B Cureus. 2024; 16(3):e57082.

PMID: 38681356 PMC: 11052699. DOI: 10.7759/cureus.57082.


Characterization of a rhabdomyosarcoma reveals a critical role for SMG7 in cancer cell viability and tumor growth.

Steiner A, Zheng Y, Tang Y Sci Rep. 2023; 13(1):10152.

PMID: 37349371 PMC: 10287741. DOI: 10.1038/s41598-023-36568-5.


Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing K-RasG12V and deficient in p53.

Saito H, Suzuki N Exp Anim. 2023; 72(4):446-453.

PMID: 37081671 PMC: 10658087. DOI: 10.1538/expanim.22-0177.


Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

Candido M, Medeiros M, Veronez L, Bastos D, Oliveira K, Pezuk J Pharmaceutics. 2023; 15(2).

PMID: 36839989 PMC: 9966033. DOI: 10.3390/pharmaceutics15020664.


K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.

Nakahata K, Simons B, Pozzo E, Shuck R, Kurenbekova L, Prudowsky Z Dis Model Mech. 2022; 15(2).

PMID: 35174853 PMC: 8844455. DOI: 10.1242/dmm.049004.